AstraZeneca Ponders a Huge $240 Billion Gilead Gamble
There are good reasons for Britain’s AstraZeneca Plc to consider what would be the biggest pharmaceuticals deal in history by combining with U.S. peer Gilead Sciences Inc. They may not be good enough to offset the risks that go with mashing…